Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Depemokimab Initiation in COPD Patients With Type 2 Inflammation (VIGILANT)
jRCT2031250639Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Annualized rate of moderate/severe exacerbations. Started Feb 2026; status: recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031250639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250639.